Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relaps...(most commonly diagnosed cancer in menacc...),Health

"We are delighted that bavituximab shrank resistant human prostate tumors in this study, an important new sign of its potential anti-cancer efficacy," said Steven W. King, president and CEO of Peregrine. "Preclinically, we have now shown that adding bavituximab equivalent antibodies to combination regimens significantly enhances the anti-tumor activity of cancer chemotherapy, of hormone deprivation therapy and of radiation therapy in prostate, breast, lung, brain and pancreatic cancers. The breadth of these potential applications supports many options for future clinical studies."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial in advanced cancer patients to assess its safety in combination with common chemotherapy agents, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

This study, entitled "Vascular Targeting Antib
'/>"/>